# NEUROCRINE BIOSCIENCES, INC. (NBIX) · Edgar & Edgarette company card

> Neurocrine Biosciences (NBIX) grew revenue 21.4% in FY2025 to $2.9 billion, operating margin 21.6% against a -15.8% median for biological products, (no diagnostic substances), equity 70.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 914475 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/NBIX) · [JSON](https://www.pops4.com/boards/company/NBIX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2.9B |
| Revenue growth, 1 year | 21.4% |
| Revenue growth per year | 26.0% |
| Operating margin | 21.6% (prior year 24.2%) |
| Net margin | 16.7% |
| Operating cash flow | $783M |
| Capital spending | $34M |
| Free cash flow | $749M |
| Cash | $713M |
| Long-term debt | — |
| Total assets | $4.6B |
| Total equity | $3.3B |
| Equity ÷ assets | 70.2% |
| Return on equity | 14.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 6.21 (safe zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.54 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $2.9B (FY2025). Experience: revenue up 21.4% on the year, up 26.0% a year over 4 years; operating margin 21.6%, down from 24.2%. Soundness: equity 70.2% of assets, return on equity 14.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.1B and $3.8B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.9B to $4.0B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 21.6% against a -15.8% median; growth 21.4% against 21.4%.

Range logged 2026-09-27, receipt 9195dc12be8163ef, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-09-28 ([filing](https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm))

## Recent filings

- 10-Q · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/0000914475-26-000054-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/0000914475-26-000053-index.htm)
- 8-K · filed 2026-09-28 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm)
- 10-Q · filed 2026-07-31 · [filing](https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/0000914475-26-000037-index.htm)
- 8-K · filed 2026-07-30 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/0000914475-26-000035-index.htm)
- 8-K · filed 2026-05-28 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000914475.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=914475

## Cite

POPS4, Edgar & Edgarette: NEUROCRINE BIOSCIENCES, INC. (NBIX) company card, from the company's own SEC filings, accessed 2026-11-12, https://www.pops4.com/boards/company/NBIX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.